L

Linear Clinical Research | Perth, Australia

Research site
(Unclaimed)
Location
1 Hospital Avenue, B-Block 1st Floor, Nedlands, Perth, Western Australia, Australia
Site insights

Top conditions

Cancer (11 trials)

Lymphoma (3 trials)

Non-Hodgkin Lymphoma (3 trials)

B-Cell Lymphoma (3 trials)

Non-Small-Cell Lung Carcinoma (2 trials)

Top treatments

Tislelizumab
Pembrolizumab
Docetaxel
SHR-1316
ALS-002158
SLN360
ARO-APOC3
SHR-1701
Elranatamab
Sildenafil

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

19 of 43
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

The goal of this clinical trial is to learn about IOS-1002 in patients with solid tumors.The main questions it aims to answer are:To determine the sa...

Enrolling
Solid Tumor, Adult
Drug: IOS-1002 + KEYTRUDA® (pembrolizumab)
Drug: IOS-1002

To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer thera...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: ERAS-601

The primary objective of this study is to evaluate safety and tolerability data when SRSD107 is administered as single and multiple SC injections to...

Enrolling
Thrombosis
Drug: Placebo
Drug: SRSD107

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Enrolling
T-cell Lymphoma
Aggressive B-Cell NHL
Drug: PRT2527
Drug: Zanubrutinib

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumorsTo evaluate t...

Enrolling
Advanced or Metastatic Solid Tumors
Drug: Trametinib
Drug: Naporafenib

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and...

Enrolling
Vasomotor Symptoms
Adult Healthy Volunteers
Drug: Placebo
Drug: GS1-144

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787
Drug: KIN-2787 and binimetinib

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. T...

Not yet enrolling
Lymphoma, Non-Hodgkin
Drug: DZD8586

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacoki...

Enrolling
Breast Cancer
Gastric Cancer
Drug: IKS014

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunog...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

This is Phase 1 study FIH to check "Dose Escalation, Dose expansion and Indication expansion". This study is AUSTRALIA only study.

Active, not recruiting
Advanced Malignant Tumors
Drug: SHR-2002 and SHR-1316

This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy...

Enrolling
Healthy Volunteers
Drug: IMG-007
Drug: Placebo

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanc...

Active, not recruiting
Advanced Solid Tumor
Non Small Cell Lung Cancer
Drug: BGB-A445
Drug: tislelizumab

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally ad...

Enrolling
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: HMBD-001

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1...

Enrolling
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Drug: HMBD-001
Drug: Nab-paclitaxel

This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of BGB-A425 and/or LBL-007 with tislel...

Enrolling
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
Drug: LBL-007
Drug: Tislelizumab

The primary objectives of this study are : to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administer...

Active, not recruiting
Locally Advanced and Metastatic Solid Tumors
Drug: Nab paclitaxel
Drug: Oxaliplatin

This is a dose escalation, Phase 1 study of ABN401 in patients with advanced solid tumors, refractory metastatic disease, or refractory locally advan...

Enrolling
Advanced Solid Tumors
Drug: ABN401- Expansion Phase
Drug: ABN401- Escalation Phase

Trial sponsors

A

Atridia (5 trials)

BeiGene logo

BeiGene (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems